New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges
This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book Chapter |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2019
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 03080naaaa2200877uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_54599 | ||
| 005 | 20210211 | ||
| 020 | |a books978-3-03921-677-2 | ||
| 020 | |a 9783039216772 | ||
| 020 | |a 9783039216765 | ||
| 024 | 7 | |a 10.3390/books978-3-03921-677-2 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 100 | 1 | |a Bakillah, Ahmed |4 auth | |
| 245 | 1 | 0 | |a New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2019 | ||
| 300 | |a 1 electronic resource (116 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic strategies. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 653 | |a apolipoprotein | ||
| 653 | |a lipids | ||
| 653 | |a risk stratification | ||
| 653 | |a proprotein convertase subtilisin-kexin type 9 (PCSK9) | ||
| 653 | |a vaspin | ||
| 653 | |a sphingolipids | ||
| 653 | |a PCSK9 | ||
| 653 | |a ceramides | ||
| 653 | |a atrial fibrillation | ||
| 653 | |a circular RNA | ||
| 653 | |a STEMI | ||
| 653 | |a cholesterol | ||
| 653 | |a lipoproteins | ||
| 653 | |a cardiovascular disease (CVD) | ||
| 653 | |a coronary artery bypass grafting | ||
| 653 | |a atherosclerosis | ||
| 653 | |a statin | ||
| 653 | |a LDL subfractions | ||
| 653 | |a acute kidney injury | ||
| 653 | |a dyslipidemia | ||
| 653 | |a gene expression | ||
| 653 | |a NSTEMI | ||
| 653 | |a NAFLD | ||
| 653 | |a hyperlipidemia | ||
| 653 | |a nonstatin | ||
| 653 | |a cholesteryl ester transfer protein | ||
| 653 | |a low-density lipoprotein cholesterol | ||
| 653 | |a anacetrapib | ||
| 653 | |a HDL | ||
| 653 | |a acute coronary syndrome | ||
| 653 | |a miRNA | ||
| 653 | |a cardiovascular risk | ||
| 653 | |a pleiotropic actions | ||
| 653 | |a genetic | ||
| 653 | |a ABCA1 | ||
| 653 | |a sdLDL | ||
| 653 | |a cardiovascular disease | ||
| 653 | |a proprotein convertase subtilisin/kexin type 9 | ||
| 653 | |a inclisiran | ||
| 653 | |a reverse cholesterol transport | ||
| 653 | |a sterol | ||
| 653 | |a small interfering RNA (siRNA) | ||
| 653 | |a RNA-binding proteins | ||
| 653 | |a cardiovascular diseases | ||
| 653 | |a NASH | ||
| 653 | |a low-density lipoprotein-cholesterol (LDL-C) | ||
| 653 | |a stroke | ||
| 653 | |a nutrigenetics | ||
| 653 | |a type 2 diabetes | ||
| 653 | |a statins | ||
| 653 | |a sphingomyelin | ||
| 653 | |a hepatic fibrosis | ||
| 653 | |a diabetes | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/1720 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/54599 |7 0 |z DOAB: description of the publication |